David is Managing Partner of F-Prime’s Tech Fund. He invests at the intersection of fintech and enterprise software, and has led investments in Flywire (NASDAQ: FLYW), Toast (NYSE: TOST), Snapdocs, Kensho (acquired by S&P Global), FutureAdvisor (acquired by BlackRock), Quovo (acquired by Plaid), EVEN Financial (acquired by MoneyLion), Vendr, 1upHealth, Notabene, TradeBlock (acquired by CoinDesk), Papaya Payments, Unison, Tradier, Axoni, Parrot Software, Canoe Intelligence, and Cloudant (acquired by IBM). David was co-founder of Sensoria and VP of Product Strategy at Into Networks, an F-Prime Capital-backed company. David was also a senior executive at Cisco Systems and held early positions with J.P. Morgan and BCG.
David graduated from Harvard Law School and earned degrees in economics and accounting from Indiana University. David is passionate about Fintech Sandbox, a nonprofit he co-founded in 2015 to serve fintech entrepreneurs by aggregating data and infrastructure for free during a startup’s development phase. Fintech Sandbox has supported 200+ startups and fostered a vibrant organization with more than 5,000 community members. He also serves on the Boards of Artists for Humanity and the Mass Fintech Hub. He is the father of two lovely teens with whom he shares the inspiration that comes from living with his wife Cindy and her poetry, stories, and pursuit of social justice.
Carl Byers brings significant operating experience in healthcare IT to his role as Partner. He was on the founding team at athenahealth, Inc. (Nasdaq: ATHN), where he served as Chief Financial Officer from 1997 to 2010. Carl was responsible for the company’s finance, legal and corporate technology teams and served as a key advisor to the CEO. When athenahealth was a private company, he built the company’s financial systems and led seven rounds of equity and subordinated debt financing. Carl led athenahealth’s 2007 Initial Public Offering, which the Wall Street Journal named as the year’s most successful. In his tenure, he also held various operational roles at different times. Prior to the founding of athenahealth, Carl was a Senior Consultant in Booz, Allen & Hamilton’s New York office, where he worked in the financial services and health insurance industries. Carl teaches finance at Harvard’s Chan School of Public Health where he is an Adjunct Lecturer on Health Policy and Management. He was appointed by Governor Charlie Baker to the Massachusetts Digital Health Council.
Carl holds a B.A. from Wesleyan and is a graduate of the Harvard Kennedy School’s Mid-Career Masters in Public Administration program.
Nihal Sinha is a Partner at F-Prime based in the London office and focuses primarily on biotech and life sciences in Europe and the US.
At F-Prime, Nihal was a member of the founding team of Orchard Therapeutics and an investor in Ensoma, Curie Bio, Charm Therapeutics, Aviado Bio, and T-Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.
Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.
Ketan Patel is a Managing Partner with F-Prime and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.
Dr. Patel focuses on investing in therapeutics and medical device companies and has served on the Board of Directors of ABK Biomedical, Aclaris Therapeutics (NASDAQ:ACRS), Avalyn Pharma, Avivomed, Bicara Therapeutics (NASDAQ: BCAX), Caplin Steriles, Comanche Biopharma, Enzene Biosciences, Eywa Pharma, Ivenix (acquired by Fresenius Kabi), Laurus Labs (NSE:LAURUSLABS), Medwell Ventures, Menlo Therapeutics (NASDAQ:MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio (NASDAQ:RLYB), and Vicept Therapeutics (acquired by Allergan).
Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.
Alex Pasteur joined F-Prime in 2012 and is a Partner based in London. Alex focuses on investments in therapeutics and the convergence of life sciences with data science. Alex serves on the boards of ARTBIO, Nodthera, Tenpoint Therapeutics, Pulmocide, Peptone, Oviva, Genomics Ltd, Owkin and Shift Bioscience. He is an observer on the board of Castor.
Alex previously served on the boards of Orchard Therapeutics (acquired by Kyowa Kirin), Acacia Pharma (acquired by Eagle Pharmaceuticals), Arvelle Therapeutics (acquired by Angelini Pharma) and as observer for Adaptimmune Therapeutics (NASDAQ: ADAP).
Alex has worked in healthcare investing since 2001. Prior to joining F-Prime, Alex worked at MVM Life Science Partners LLP in the USA and Europe. Alex holds a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.
Jon Lim is a Managing Partner who joined F-Prime in 2011 to launch our dedicated efforts in Healthtech + Services. His investments include F-Prime’s investments in Liazon (acquired by Towers Watson), PatientPing (acquired by Appriss Heath, now Bamboo Health), VitalWare (acquired by Health Catalyst), Artemis Health (acquired by Nomi Health), Lumere (acquired by Global Healthcare Exchange), Blue Rabbit (acquired by Wedgewood Pharmacy), Protenus (acquired by Bluesight), Benchling, BenchSci, Centivo, Equip Health, Kyruus, NOCD, OncoveryCare, Proximie, Rippl, TraceLink, US HealthVest and WelbeHealth. Jon was previously a Principal at Polaris Partners, where he was part of the teams that led investments in Phytel (acquired by IBM), Egnyte, Recurly, and Ocular Therapeutix (NASDAQ: OCUL). Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business.
Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.
In Loving Memory of Thomas Russell Beck, M.D.
August 3, 1949 – May 25, 2020
It is with a profound and deep sense of sadness that F-Prime says goodbye to Executive Partner Tom Beck. Tom was an essential and beloved friend and colleague to us all. We will greatly miss Tom’s expertise, wisdom, rolled-up-sleeves hands-on hard work, avuncular guidance, generosity, sense of humor and indefatigable bon homie that he maintained to the very end. Through his work, Tom made a big impact on the biotechnology industry, and an even bigger impact on all of us.
Robert Weisskoff, Senior Partner, joined F-Prime in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.
Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.
Robert serves on the Board of Directors of Adela, Countable Labs, Plasmagen Biosciences, RareCyte, Shinobi Therapeutics, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Caribou Biosciences (NASDAQ: CRBU), Farapulse (acquired by Boston Scientific), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE: LAURUSLABS), Structure Therapeutics (NASDAQ: GPCR), Surface Oncology (NASDAQ: SURF), Tetraphase (NASDAQ: TTPH), Transave (NASDAQ: INSM), Topaz (acquired by Sanofi Pasteur), ViewRay (NASDAQ: VRAY) and Xilio Therapeutics (NASDAQ: XLO).
Stephen Knight joined F-Prime in 2003 where he serves as President and Senior Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI), Skyline Therapeutics, and Xaira Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA), and Semma Therapeutics (acquired by Vertex).
Prior to joining F-Prime, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.